A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD
NCT ID: NCT05905133
Last Updated: 2023-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
360 participants
INTERVENTIONAL
2023-07-15
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The subjects will receive a subcutaneous injection of CBP-201 600 mg (4 mL in total, 2 injections of 2 mL each in different sites) on Day1, begin to receive a subcutaneous injection of CBP-201 300 mg (2 mL) from Week2, and receive CBP-201 300 mg (2 mL) every 2 weeks thereafter until Week10.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CBP-201
The subjects will receive CBP-201 600 mg (4 mL in total, 2 injections of 2 mL each in different sites) on Day1, begin to receive a subcutaneous injection of CBP-201 300 mg (2 mL) from Week2, and receive CBP-201 300 mg (2 mL) every 2 weeks thereafter until Week10.
CBP-201
subcutaneous injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CBP-201
subcutaneous injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosed with atopic dermatitis (according to the American Academy of Dermatology's Guidelines of care for the management of atopic dermatitis, 2014\[1\]) at the time of screening, and meeting all the 4 criteria below:
1. Suffering from the disease for more than 1 year at the time of screening;
2. At the screening and baseline visit, IGA score ≥ 3 (according to the validated Investigator Global Assessment for Atopic Dermatitis \[vIGA-AD™\] scale);
3. EASI score ≥ 12;
4. Percentage of total BSA affected by AD ≥ 10%.
3. Female subjects of childbearing potential (FCBP) and male subjects who have not undergone vasectomy must agree to take highly effective contraceptive measures during the entire study period (from the signing of informed consent forms (ICFs) to the 8-week follow-up period after discontinuation of study drug). Postmenopausal women (determined by testing follicle stimulating hormone \[FSH\]; defined as the women who have had amenorrhea for at least 12 consecutive months without using drugs known to cause amenorrhea, and have a recorded FSH level greater than 40 mIU/mL or in the postmenopausal range) and women with a record of surgical sterilization (i.e., tubal ligation or hysterectomy or bilateral oophorectomy) before the screening visit can be considered infertile.
Highly effective contraceptive measures include:
i. Abstinence (acceptable only if it is part of the subject's routine lifestyle); ii. Hormones (oral, patch, ring, injection, implant) combined with male condoms. This measure must be used at least 30 days before the first study drug administration. Otherwise, another acceptable method of contraception must be used; iii. Intrauterine device (IUD) combined with male condoms.
4. Subjects are willing and able to comply with study visits and related procedures.
5. Subjects have the ability to learn the study requirements and process, and voluntarily take part in the clinical trial and sign an ICF.
Exclusion Criteria
2. Have received any of the following topical treatments within 2 weeks before D1 visit: phosphodiesterase-4 (PDE-4) inhibitors, Janus kinase (JAK) inhibitors, or aromatic hydrocarbon receptor agonists.
3. Have received systemic treatment with corticosteroids (except for corticosteroid inhalers and nasal sprays) or other immunosuppressive/immunomodulatory agents (including but not limited to cyclosporine, mycophenolate mofetil, azathioprine, methotrexate, JAK inhibitors, and various biological agents) within 2 weeks before D1 visit or 5 drug half-lives (if known), whichever is longer.
4. Have received treatment with immune cell depletion agents (e.g., rituximab) within 6 months before D1 visit.
5. Have received any investigational drug/treatment within 4 weeks before D1 visit or 5 drug half-lives (if known), whichever is longer.
6. Other skin complications in addition to AD that may interfere with the study assessments.
7. There is a known or suspected history of immunosuppression/immunodeficiency within 6 months before D1 visit (including but not limited to a history of invasive opportunistic infections, such as aspergillosis, coccidiosis, histoplasmosis, acquired immunodeficiency syndrome (AIDS), listeriosis, or Pneumocystis, even if the infection has subsided), or there is an abnormally frequently recurrent or persistent infection.
8. Received systemic treatment with anti-infective drugs (including but not limited to antibiotics, antiviral drugs, antiparasitic drugs, antiprotozoal drugs, or antifungal drugs) due to acute or chronic infection within 1 week before D1 visit (after the infection subsides, the subjects can be rescreened).
9. History of malignant tumor within 5 years before D1 visit (except for completely cured cervical carcinoma in situ or non-metastatic cutaneous squamous cell carcinoma or basal cell carcinoma).
10. History of parasite infection within 6 months before D1 visit.
11. Positive for hepatitis B surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb) and HBV-DNA, or positive for hepatitis C antibody and HCV ribonucleic acid (RNA) polymerase chain reaction, or serologically positive for human immunodeficiency virus (HIV) at the screening visit.
12. Subjects with active tuberculosis, latent tuberculosis, or a history of nontuberculous mycobacterial infection at screening;
Note:
* Unless there is a clear medical record proving that the subject has received adequate treatment and is currently able to start receiving biological treatment (based on the medical judgment of the investigator and/or infectious disease specialist);
* If needed, an interferon gamma release assay may be used to assist diagnosis of suspected tuberculosis.
13. Any of the following laboratory test abnormalities at the screening visit:
1. Aspartate aminotransferase or alanine aminotransferase \> 2 times the upper limit of normal (ULN);
2. Total bilirubin \> 1.5 × ULN;
3. Serum creatinine \> 1.2 × ULN;
4. White blood cell count \< 3.0 × 109/L or ≥ 14 × 109/L; Note: If the subjects have the above laboratory test abnormalities at screening, after being assessed as necessary by the investigator, they are allowed to receive a retest on another day within 28 days of the screening period, and those qualified for the retest are permitted to be enrolled (it is forbidden to conduct drug intervention for those laboratory test abnormalities before retest).
14. History of hypersensitivity to L-histidine, trehalose or Tween (polysorbate) 80, or systemic hypersensitivity reactions to any biological agents (except local injection site reactions).
15. History of alcohol or drug abuse within 2 years before D1 visit.
16. Have been vaccinated with (attenuated) live vaccine within 8 weeks before D1 visit, or planning to be vaccinated during the study period.
17. Planning to undergo major surgical operations during the study period.
18. Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period.
19. Any other conditions (e.g., those may increase the risks of the subjects, or may affect/interfere with the assessment of the study) that the investigator deems unsuitable for participation in this study, including but not limited to: prior or current physical or mental illness, clinically significant physical examination results, vital signs, or safety laboratory test abnormalities at screening. The specific reasons for subjects excluded due to this criterion will be indicated in the study documents (including medical records and electronic case report form (eCRF)).
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Connect Biopharm LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Suzhou Connect
Role: STUDY_DIRECTOR
Connect Biopharm LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Connect Investigative Site 01
Beijing, Beijing Municipality, China
Connect Investigative Site 41
Beijing, Beijing Municipality, China
Connect Investigative Site 14
Fuzhou, Fujian, China
Connect Investigative Site 25
Fuzhou, Fujian, China
Connect Investigative Site 03
Guangzhou, Guangdong, China
Connect Investigative Site 11
Guangzhou, Guangdong, China
Connect Investigative Site 13
Guangzhou, Guangdong, China
Connect Investigative Site 20
Guangzhou, Guangdong, China
Connect Investigative Site 22
Shenzhen, Guangdong, China
Connect Investigative Site 31
Nanning, Guangxi, China
Connect Investigative Site 16
Haikou, Hainan, China
Connect Investigative Site 17
Haikou, Hainan, China
Connect Investigative Site 19
Nanyang, Henan, China
Connect Investigative Site 27
Wuhan, Hubei, China
Connect Investigative Site 28
Yichang, Hubei, China
Connect Investigative Site 26
Changsha, Hunan, China
Connect Investigative Site 34
Nanjing, Jiangsu, China
Connect Investigative Site 39
Suzhou, Jiangsu, China
Connect Investigative Site 05
Zhenjiang, Jiangsu, China
Connect Investigative Site 29
Shenyang, Liaoning, China
Connect Investigative Site 40
Jiangxi, Nanchang, China
Connect Investigative Site 24
Baotou, Nei Monggol, China
Connect Investigative Site 18
Yinchuan, Ningxia, China
Connect Investigative Site 30
Dongying, Shandong, China
Connect Investigative Site 21
Jinan, Shandong, China
Connect Investigative Site 35
Jinan, Shandong, China
Connect Investigative Site 36
Shanghai, Shanghai Municipality, China
Connect Investigative Site 10
Taiyuan, Shanxi, China
Connect Investigative Site 06
Xi’an, Shanxi, China
Connect Investigative Site 15
Yuncheng, Shanxi, China
Connect Investigative Site 23
Chengdu, Sichuan, China
Connect Investigative Site 02
Tianjin, Tianjin Municipality, China
Connect Investigative Site 09
Ürümqi, Xinjiang, China
Connect Investigative Site 07
Hangzhou, Zhejiang, China
Connect Investigative Site 08
Hangzhou, Zhejiang, China
Connect Investigative Site 33
Hangzhou, Zhejiang, China
Connect Investigative Site 37
Hangzhou, Zhejiang, China
Connect Investigative Site 32
Ningbo, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CBP-201-CN003
Identifier Type: -
Identifier Source: org_study_id